As of 05 March 2025, the Health Technology Assessment (HTA) Council makes public its preliminary recommendation on the non-inclusion in the PNF and thus the non-government financing of hexavalent vaccine, for stakeholder feedback/comments. Overall, the HTA Council recognizes that hexavalent vaccines will result in a simpler immunization schedule and thus, better compliance and easier implementation. continue reading : HTA Council Preliminary Recommendation on Hexavalent Vaccine for active immunization of infants to prevent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis b, and invasive disease due to Haemophilus influenzae type b
HTA Council Preliminary Recommendation on Fecal Immunohistochemical Test (FIT) for colorectal cancer in apparently healthy adults aged 50 years and above
As of 26 February 2025, the Health Technology Assessment (HTA) Council hereby makes public its preliminary recommendation on the possible financing of Fecal immunohistochemical test (FIT) as an annual screening test for colorectal cancer for apparently healthy adults aged 50 years and above by the Department of Health (DOH) and/or PhilHealth, for stakeholder feedback/comments. Based continue reading : HTA Council Preliminary Recommendation on Fecal Immunohistochemical Test (FIT) for colorectal cancer in apparently healthy adults aged 50 years and above
HTA Council Preliminary Recommendation on High-risk Human Papillomavirus (HPV) DNA Test and Visual Inspection with Acetic Acid
Published on 11 February 2025 As of 11 February 2025, the Health Technology Assessment (HTA) Council hereby makes public its preliminary recommendations on the possible financing of High Risk Human Papillomavirus (HrHPV) DNA Test and Visual Inspection with Acetic Acid (VIA) by Department of Health (DOH) and/or PhilHealth, for stakeholder feedback/comments. These health technologies were continue reading : HTA Council Preliminary Recommendation on High-risk Human Papillomavirus (HPV) DNA Test and Visual Inspection with Acetic Acid
CALL FOR PROPOSALS: HTA Research Agenda Program [HTA Research Topics 2024 – Batch 3 & 4 [REPOST of FEC topics and Cycle 1 topics for Economic Assessments]
Published 16 January 2025 This call consists of prioritized health technology topics that underwent clinical assessment under the HTA general track and are proceeding to economic assessment which includes economic evaluation (EE), budget impact analysis (BIA), and household financial impact (HFI) analysis to assess both the value for money of a health technology and its continue reading : CALL FOR PROPOSALS: HTA Research Agenda Program [HTA Research Topics 2024 – Batch 3 & 4 [REPOST of FEC topics and Cycle 1 topics for Economic Assessments]
HTA Council Preliminary Recommendation on Abacavir/Lamivudine Tablet, Levonorgestrel Intrauterine Delivery (IUD) System, Levonorgestrel Subdermal Implant, Multiple Micronutrient Supplement Capsule, and Sodium Chloride + Potassium Chloride + Calcium Lactate Pentahydrate Powder for Reconstitution
Update as of 25 November 2024 : Since the public consultation and appeals period for the HTA Council Preliminary Recommendation on Abacavir/Lamivudine Tablet, Levonorgestrel Intrauterine Delivery (IUD) System, Levonorgestrel Subdermal Implant, Multiple Micronutrient Supplement Capsule, and Sodium Chloride + Potassium Chloride + Calcium Lactate Pentahydrate Powder for Reconstitution ended on 22 November 2024 without valid appeals received, this continue reading : HTA Council Preliminary Recommendation on Abacavir/Lamivudine Tablet, Levonorgestrel Intrauterine Delivery (IUD) System, Levonorgestrel Subdermal Implant, Multiple Micronutrient Supplement Capsule, and Sodium Chloride + Potassium Chloride + Calcium Lactate Pentahydrate Powder for Reconstitution